HOMEPAGE Cannabis Five of the key emerging trends in the booming global medical cannabis and cannabinoid medicine industries… Read more WHITE PAPER Patents: A Key Factor in Winning the Cannabis Arms Race A new white paper from Fasken law firm asserts that the early filing of patents for innovative products is…
BACK TO HOME Rare Diseases BACK TO HOME Neil Dugdale VP & GM, UK & RoI, Sobi Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to…
BACK TO HOME Rare Diseases BACK TO HOME Mythbusting: Patient Access to Rare Disease Treatments After her son was diagnosed with SYNGAP1 – an extremely rare gene mutation – Monica founded Bridge the Gap – SYNGAP Education and Research Foundation to support families of those suffering from the illness and…
BACK TO HOME Rare Diseases BACK TO HOME Rethinking Clinical Trials in Rare Diseases Drug development in rare diseases is currently in a very exciting time. While much of the focus is on the scientific advances, access to rare disease patients and well-designed clinical trials are also…
BACK TO HOME Rare Diseases BACK TO HOME Top 10 Global Orphan Drug Companies Ranking 2017 The top 10 companies in the world ranked by global orphan drug sales and market share in 2017. Swiss giants Novartis and Roche take the top two places, followed by American…
BACK TO HOME Rare Diseases BACK TO HOME Rare Disease Company Acquisitions Continue Apace Following on from Johnson & Johnson’s acquisition of Actelion in January 2017 and Takeda’s takeover of Shire two years later, pharma multinationals’ rush to snap up rare disease specialists continues with Ipsen’s proposed…
BACK TO HOME Rare Diseases BACK TO HOME 5 Key Trends in Orphan Drugs & Rare Diseases Long regarded as a neglected backwater within the drug discovery landscape and the preserve of only a handful of niche players, the rare disease space has been undergoing an extraordinary turnaround in…
HOMEPAGE Rare Diseases Long regarded as a neglected backwater within the drug discovery landscape and the preserve of only a handful of niche players, the rare disease space has been undergoing an extraordinary turnaround in fortunes of late. According to EvaluatePharma’s forecasts, orphan drug sales are set to grow 11 percent each…
BACK TO HOME European Mid-Caps BACK TO HOME Servier’s Olivier Laureau: Change Instigator Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but nonetheless formidably successful, Servier…
BACK TO HOME European Mid-Caps BACK TO HOME Top European Pharma Mid-Cap Ranking 2019 The European MidPharma Performance Ranking 2019 is taken from The Novasecta European Midpharma Report 2019, which examines how European mid-cap pharma companies are surviving and thriving. With scores assigned to R&D investment, commercial revenues…
BACK TO HOME European Mid-Caps BACK TO HOME Spanish Mid-Caps: Going Global Despite the Spanish economy and pharmaceutical market’s steady growth, many local players are becoming cognizant of the limitations and risks of operating within a single market. Therefore, these small to mid-cap local companies are taking…
BACK TO HOME European Mid-Caps BACK TO HOME 5 Top European Mid-Cap CEOs To Know Bringing together insights from the heads of some of Europe’s most prominent mid-cap pharma firms. The leaders of Ipsen, Genmab, Pierre Fabre, Esteve and Servier outline the strategic directions in which their…
See our Cookie Privacy Policy Here
